Abstract | OBJECTIVE: METHODS: RESULTS: Before the start of therapy, transfusion requirements averaged 3.5 units/month over a 1.5-11 month period of observation. Patients were then treated with a combination of ethynil estradiol 30 microg and noretisterone 1.5 mg daily. During follow-up (range 3-12 months), bleeding did not recur in four patients; in one patient, treatment with estrogen progesterone decreased the need for transfusions from 4 units/month to 1.4 unit/month; this patient stopped the treatment inadvertently after 6 months and severe anemia recurred with a need for 4 units of blood in the following month; reintroduction of the treatment resulted in an increase of hemoglobin levels without the need for blood transfusions during the following 4 months. In the last patient, a 5-month treatment did not improve chronic bleeding. CONCLUSIONS: The present study suggests that estrogen- progesterone therapy is useful in the treatment of chronic bleeding related to GAVE; however, these findings require confirmation by a controlled trial.
|
Authors | A Tran, J P Villeneuve, M Bilodeau, B Willems, D Marleau, D Fenyves, R Parent, G Pomier-Layrargues |
Journal | The American journal of gastroenterology
(Am J Gastroenterol)
Vol. 94
Issue 10
Pg. 2909-11
(Oct 1999)
ISSN: 0002-9270 [Print] United States |
PMID | 10520843
(Publication Type: Journal Article)
|
Chemical References |
- Estradiol Congeners
- Progesterone Congeners
- Ethinyl Estradiol
- Norethindrone Acetate
- Norethindrone
|
Topics |
- Aged
- Aged, 80 and over
- Chronic Disease
- Drug Evaluation
- Drug Therapy, Combination
- Estradiol Congeners
(administration & dosage)
- Ethinyl Estradiol
(administration & dosage)
- Gastric Antral Vascular Ectasia
(complications)
- Gastrointestinal Hemorrhage
(drug therapy)
- Humans
- Liver Cirrhosis
(complications)
- Middle Aged
- Norethindrone
(administration & dosage, analogs & derivatives)
- Norethindrone Acetate
- Pilot Projects
- Progesterone Congeners
(administration & dosage)
- Recurrence
|